|
1
|
Naus E, Derweduwe M, Lampi Y, Claeys A, Pauwels J, Langenberg T, Claes F, Xu J, Haemels V, Atak ZK, van der Kant R, Van Durme J, De Baets G, Ligon KL, Fiers M, Gevaert K, Aerts S, Rousseau F, Schymkowitz J, De Smet F. Reduced Levels of Misfolded and Aggregated Mutant p53 by Proteostatic Activation. Cells 2023; 12:cells12060960. [PMID: 36980299 PMCID: PMC10047295 DOI: 10.3390/cells12060960] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/31/2021] [Revised: 12/21/2022] [Accepted: 02/27/2023] [Indexed: 03/29/2023] Open
Abstract
In malignant cancer, excessive amounts of mutant p53 often lead to its aggregation, a feature that was recently identified as druggable. Here, we describe that induction of a heat shock-related stress response mediated by Foldlin, a small-molecule tool compound, reduces the protein levels of misfolded/aggregated mutant p53, while contact mutants or wild-type p53 remain largely unaffected. Foldlin also prevented the formation of stress-induced p53 nuclear inclusion bodies. Despite our inability to identify a specific molecular target, Foldlin also reduced protein levels of aggregating SOD1 variants. Finally, by screening a library of 778 FDA-approved compounds for their ability to reduce misfolded mutant p53, we identified the proteasome inhibitor Bortezomib with similar cellular effects as Foldlin. Overall, the induction of a cellular heat shock response seems to be an effective strategy to deal with pathological protein aggregation. It remains to be seen however, how this strategy can be translated to a clinical setting.
Collapse
Affiliation(s)
- Evelyne Naus
- VIB-KU Leuven Center for Brain & Disease Research, Herestraat 49, 3000 Leuven, Belgium; (E.N.); (Y.L.); (T.L.); (F.C.); (J.X.); (Z.K.A.); (R.v.d.K.); (J.V.D.); (G.D.B.); (M.F.); (S.A.); (F.R.); (J.S.)
- Switch Laboratory, Department for Cellular and Molecular Medicine, Katholieke Universiteit Leuven, 3000 Leuven, Belgium
| | - Marleen Derweduwe
- The Laboratory for Precision Cancer Medicine, Translational Cell and Tissue Research Unit, Department of Imaging and Pathology, Katholieke Universiteit Leuven, 3000 Leuven, Belgium (V.H.); (K.G.)
| | - Youlia Lampi
- VIB-KU Leuven Center for Brain & Disease Research, Herestraat 49, 3000 Leuven, Belgium; (E.N.); (Y.L.); (T.L.); (F.C.); (J.X.); (Z.K.A.); (R.v.d.K.); (J.V.D.); (G.D.B.); (M.F.); (S.A.); (F.R.); (J.S.)
- Switch Laboratory, Department for Cellular and Molecular Medicine, Katholieke Universiteit Leuven, 3000 Leuven, Belgium
| | - Annelies Claeys
- The Laboratory for Precision Cancer Medicine, Translational Cell and Tissue Research Unit, Department of Imaging and Pathology, Katholieke Universiteit Leuven, 3000 Leuven, Belgium (V.H.); (K.G.)
| | - Jarne Pauwels
- VIB-UGent Center for Medical Biotechnology, 9052 Ghent, Belgium;
- Department of Biomolecular Medicine, Ghent University, 9052 Ghent, Belgium
| | - Tobias Langenberg
- VIB-KU Leuven Center for Brain & Disease Research, Herestraat 49, 3000 Leuven, Belgium; (E.N.); (Y.L.); (T.L.); (F.C.); (J.X.); (Z.K.A.); (R.v.d.K.); (J.V.D.); (G.D.B.); (M.F.); (S.A.); (F.R.); (J.S.)
- Switch Laboratory, Department for Cellular and Molecular Medicine, Katholieke Universiteit Leuven, 3000 Leuven, Belgium
| | - Filip Claes
- VIB-KU Leuven Center for Brain & Disease Research, Herestraat 49, 3000 Leuven, Belgium; (E.N.); (Y.L.); (T.L.); (F.C.); (J.X.); (Z.K.A.); (R.v.d.K.); (J.V.D.); (G.D.B.); (M.F.); (S.A.); (F.R.); (J.S.)
- Switch Laboratory, Department for Cellular and Molecular Medicine, Katholieke Universiteit Leuven, 3000 Leuven, Belgium
| | - Jie Xu
- VIB-KU Leuven Center for Brain & Disease Research, Herestraat 49, 3000 Leuven, Belgium; (E.N.); (Y.L.); (T.L.); (F.C.); (J.X.); (Z.K.A.); (R.v.d.K.); (J.V.D.); (G.D.B.); (M.F.); (S.A.); (F.R.); (J.S.)
- Switch Laboratory, Department for Cellular and Molecular Medicine, Katholieke Universiteit Leuven, 3000 Leuven, Belgium
| | - Veerle Haemels
- The Laboratory for Precision Cancer Medicine, Translational Cell and Tissue Research Unit, Department of Imaging and Pathology, Katholieke Universiteit Leuven, 3000 Leuven, Belgium (V.H.); (K.G.)
| | - Zeynep Kalender Atak
- VIB-KU Leuven Center for Brain & Disease Research, Herestraat 49, 3000 Leuven, Belgium; (E.N.); (Y.L.); (T.L.); (F.C.); (J.X.); (Z.K.A.); (R.v.d.K.); (J.V.D.); (G.D.B.); (M.F.); (S.A.); (F.R.); (J.S.)
- Laboratory of Computational Biology, Center for Human Genetics, Katholieke Universiteit Leuven, 3000 Leuven, Belgium
| | - Rob van der Kant
- VIB-KU Leuven Center for Brain & Disease Research, Herestraat 49, 3000 Leuven, Belgium; (E.N.); (Y.L.); (T.L.); (F.C.); (J.X.); (Z.K.A.); (R.v.d.K.); (J.V.D.); (G.D.B.); (M.F.); (S.A.); (F.R.); (J.S.)
- Switch Laboratory, Department for Cellular and Molecular Medicine, Katholieke Universiteit Leuven, 3000 Leuven, Belgium
| | - Joost Van Durme
- VIB-KU Leuven Center for Brain & Disease Research, Herestraat 49, 3000 Leuven, Belgium; (E.N.); (Y.L.); (T.L.); (F.C.); (J.X.); (Z.K.A.); (R.v.d.K.); (J.V.D.); (G.D.B.); (M.F.); (S.A.); (F.R.); (J.S.)
- Switch Laboratory, Department for Cellular and Molecular Medicine, Katholieke Universiteit Leuven, 3000 Leuven, Belgium
| | - Greet De Baets
- VIB-KU Leuven Center for Brain & Disease Research, Herestraat 49, 3000 Leuven, Belgium; (E.N.); (Y.L.); (T.L.); (F.C.); (J.X.); (Z.K.A.); (R.v.d.K.); (J.V.D.); (G.D.B.); (M.F.); (S.A.); (F.R.); (J.S.)
- Switch Laboratory, Department for Cellular and Molecular Medicine, Katholieke Universiteit Leuven, 3000 Leuven, Belgium
| | - Keith L. Ligon
- Department of Medical Oncology, Center for Molecular Oncologic Pathology, Dana-Farber Cancer Institute, Boston, MA 02215, USA;
- The Broad Institute, Cambridge, MA 02142, USA
- Department of Pathology, Division of Neuropathology, Brigham and Women’s Hospital and Children’s Hospital Boston, Boston, MA 02215, USA
- Department of Pathology, Harvard Medical School, Boston, MA 02215, USA
| | - Mark Fiers
- VIB-KU Leuven Center for Brain & Disease Research, Herestraat 49, 3000 Leuven, Belgium; (E.N.); (Y.L.); (T.L.); (F.C.); (J.X.); (Z.K.A.); (R.v.d.K.); (J.V.D.); (G.D.B.); (M.F.); (S.A.); (F.R.); (J.S.)
- Department of Medical Oncology, Center for Molecular Oncologic Pathology, Dana-Farber Cancer Institute, Boston, MA 02215, USA;
| | - Kris Gevaert
- The Laboratory for Precision Cancer Medicine, Translational Cell and Tissue Research Unit, Department of Imaging and Pathology, Katholieke Universiteit Leuven, 3000 Leuven, Belgium (V.H.); (K.G.)
- VIB-UGent Center for Medical Biotechnology, 9052 Ghent, Belgium;
| | - Stein Aerts
- VIB-KU Leuven Center for Brain & Disease Research, Herestraat 49, 3000 Leuven, Belgium; (E.N.); (Y.L.); (T.L.); (F.C.); (J.X.); (Z.K.A.); (R.v.d.K.); (J.V.D.); (G.D.B.); (M.F.); (S.A.); (F.R.); (J.S.)
- Laboratory of Computational Biology, Center for Human Genetics, Katholieke Universiteit Leuven, 3000 Leuven, Belgium
| | - Frederic Rousseau
- VIB-KU Leuven Center for Brain & Disease Research, Herestraat 49, 3000 Leuven, Belgium; (E.N.); (Y.L.); (T.L.); (F.C.); (J.X.); (Z.K.A.); (R.v.d.K.); (J.V.D.); (G.D.B.); (M.F.); (S.A.); (F.R.); (J.S.)
- Switch Laboratory, Department for Cellular and Molecular Medicine, Katholieke Universiteit Leuven, 3000 Leuven, Belgium
| | - Joost Schymkowitz
- VIB-KU Leuven Center for Brain & Disease Research, Herestraat 49, 3000 Leuven, Belgium; (E.N.); (Y.L.); (T.L.); (F.C.); (J.X.); (Z.K.A.); (R.v.d.K.); (J.V.D.); (G.D.B.); (M.F.); (S.A.); (F.R.); (J.S.)
- Switch Laboratory, Department for Cellular and Molecular Medicine, Katholieke Universiteit Leuven, 3000 Leuven, Belgium
| | - Frederik De Smet
- The Laboratory for Precision Cancer Medicine, Translational Cell and Tissue Research Unit, Department of Imaging and Pathology, Katholieke Universiteit Leuven, 3000 Leuven, Belgium (V.H.); (K.G.)
- Correspondence:
| |
Collapse
|
|
2
|
Nair PM, Starkey MR, Haw TJ, Liu G, Horvat JC, Morris JC, Verrills NM, Clark AR, Ammit AJ, Hansbro PM. Targeting PP2A and proteasome activity ameliorates features of allergic airway disease in mice. Allergy 2017; 72:1891-1903. [PMID: 28543283 DOI: 10.1111/all.13212] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 05/20/2017] [Indexed: 12/22/2022]
Abstract
BACKGROUND Asthma is an allergic airway disease (AAD) caused by aberrant immune responses to allergens. Protein phosphatase-2A (PP2A) is an abundant serine/threonine phosphatase with anti-inflammatory activity. The ubiquitin proteasome system (UPS) controls many cellular processes, including the initiation of inflammatory responses by protein degradation. We assessed whether enhancing PP2A activity with fingolimod (FTY720) or 2-amino-4-(4-(heptyloxy) phenyl)-2-methylbutan-1-ol (AAL(S) ), or inhibiting proteasome activity with bortezomib (BORT), could suppress experimental AAD. METHODS Acute AAD was induced in C57BL/6 mice by intraperitoneal sensitization with ovalbumin (OVA) in combination with intranasal (i.n) exposure to OVA. Chronic AAD was induced in mice with prolonged i.n exposure to crude house dust mite (HDM) extract. Mice were treated with vehicle, FTY720, AAL(S) , BORT or AAL(S) +BORT and hallmark features of AAD assessed. RESULTS AAL(S) reduced the severity of acute AAD by suppressing tissue eosinophils and inflammation, mucus-secreting cell (MSC) numbers, type 2-associated cytokines (interleukin (IL)-33, thymic stromal lymphopoietin, IL-5 and IL-13), serum immunoglobulin (Ig)E and airway hyper-responsiveness (AHR). FTY720 only suppressed tissue inflammation and IgE. BORT reduced bronchoalveolar lavage fluid (BALF) and tissue eosinophils and inflammation, IL-5, IL-13 and AHR. Combined treatment with AAL(S) +BORT had complementary effects and suppressed BALF and tissue eosinophils and inflammation, MSC numbers, reduced the production of type 2 cytokines and AHR. AAL(S) , BORT and AAL(S) +BORT also reduced airway remodelling in chronic AAD. CONCLUSION These findings highlight the potential of combination therapies that enhance PP2A and inhibit proteasome activity as novel therapeutic strategies for asthma.
Collapse
Affiliation(s)
- P. M. Nair
- Priority Research Centres for Healthy Lungs; Grow up Well and Cancer Research, Innovation and Translation; University of Newcastle & Hunter Medical Research Institute; New Lambton Heights NSW Australia
- Faculty of Health and Medicine; School of Biomedical Sciences and Pharmacy; University of Newcastle; Callaghan NSW Australia
| | - M. R. Starkey
- Priority Research Centres for Healthy Lungs; Grow up Well and Cancer Research, Innovation and Translation; University of Newcastle & Hunter Medical Research Institute; New Lambton Heights NSW Australia
- Faculty of Health and Medicine; School of Biomedical Sciences and Pharmacy; University of Newcastle; Callaghan NSW Australia
| | - T. J. Haw
- Priority Research Centres for Healthy Lungs; Grow up Well and Cancer Research, Innovation and Translation; University of Newcastle & Hunter Medical Research Institute; New Lambton Heights NSW Australia
- Faculty of Health and Medicine; School of Biomedical Sciences and Pharmacy; University of Newcastle; Callaghan NSW Australia
| | - G. Liu
- Priority Research Centres for Healthy Lungs; Grow up Well and Cancer Research, Innovation and Translation; University of Newcastle & Hunter Medical Research Institute; New Lambton Heights NSW Australia
- Faculty of Health and Medicine; School of Biomedical Sciences and Pharmacy; University of Newcastle; Callaghan NSW Australia
| | - J. C. Horvat
- Priority Research Centres for Healthy Lungs; Grow up Well and Cancer Research, Innovation and Translation; University of Newcastle & Hunter Medical Research Institute; New Lambton Heights NSW Australia
- Faculty of Health and Medicine; School of Biomedical Sciences and Pharmacy; University of Newcastle; Callaghan NSW Australia
| | - J. C. Morris
- School of Chemistry; University of New South Wales; Sydney NSW Australia
| | - N. M. Verrills
- Priority Research Centres for Healthy Lungs; Grow up Well and Cancer Research, Innovation and Translation; University of Newcastle & Hunter Medical Research Institute; New Lambton Heights NSW Australia
- Faculty of Health and Medicine; School of Biomedical Sciences and Pharmacy; University of Newcastle; Callaghan NSW Australia
| | - A. R. Clark
- Institute of Inflammation and Ageing; College of Medical and Dental Sciences; University of Birmingham; Birmingham UK
| | - A. J. Ammit
- Woolcock Emphysema Centre; Woolcock Institute of Medical Research; University of Sydney; Sydney NSW Australia
- Faculty of Science; School of Life Sciences; University of Technology Sydney; Sydney NSW Australia
| | - P. M. Hansbro
- Priority Research Centres for Healthy Lungs; Grow up Well and Cancer Research, Innovation and Translation; University of Newcastle & Hunter Medical Research Institute; New Lambton Heights NSW Australia
- Faculty of Health and Medicine; School of Biomedical Sciences and Pharmacy; University of Newcastle; Callaghan NSW Australia
| |
Collapse
|
|
3
|
Gao W, Guo WJ, Hou DY, Yang GZ, Wu Y, Li YC, Leng Y, Tang Y, Xu L, Liu JM, Wang H, Wang X, Zhang J, Zhao WS, Chen WM, Zhang L. Autoantibodies against β 1-adrenergic receptor: response to induction therapy with bortezomib-containing regimens for multiple myeloma patients. Leuk Lymphoma 2017; 59:717-724. [PMID: 28679329 DOI: 10.1080/10428194.2017.1344904] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
Abstract
This study aims to investigate the predictive value of pre-chemotherapy β1R-AABs by evaluating the response of newly diagnosed symptomatic multiple myeloma (MM) patients to their treatment with a bortezomib-containing regimen. Forty-five de novo MM patients and 50 normal controls (NCs) were prospectively enrolled in this study. Serum titers of β1R-AABs were detected by ELISA. These 45 MM patients were divided into two groups (positive and negative groups) according to their β1R-AABs. Follow-up examinations were performed on these patients during chemotherapy induction. The final analysis covered all 45 MM patients, including 19 patients who were positive for MM and 26 patients who were negative for MM. Multivariate analysis revealed that pre-chemotherapy β1R-AABs are possibly independent predictors for less than very good partial response (VGPR) after the bortezomib-containing regimen treatment (odds ratio: 5.967, 95% confidence interval: 1.513-23.531; p = .011). This study demonstrates for the first time that the presence of β1R-AABs is associated with MM. Pre-chemotherapy β1R-AABs are independent predictors for less than VGPR in de novo MM patients after the bortezomib-containing regimen was administrated. Bortezomib might not significantly give rise to cardiac impairment in MM patients.
Collapse
Affiliation(s)
- Wen Gao
- a Department of Hematology , Myeloma Research Center of Beijing, Beijing Chao-Yang Hospital, Capital Medical University , Beijing , China
| | - Wen-Jia Guo
- b Department of Cardiology , Heart Failure Center, Capital Medical University, Beijing Chao-Yang Hospital , Beijing , China.,c Beijing Key Laboratory of Metabolic Disorders Related Cardiovascular Diseases , Beijing , China
| | - Dong-Yan Hou
- b Department of Cardiology , Heart Failure Center, Capital Medical University, Beijing Chao-Yang Hospital , Beijing , China.,c Beijing Key Laboratory of Metabolic Disorders Related Cardiovascular Diseases , Beijing , China
| | - Guang-Zhong Yang
- a Department of Hematology , Myeloma Research Center of Beijing, Beijing Chao-Yang Hospital, Capital Medical University , Beijing , China
| | - Yin Wu
- a Department of Hematology , Myeloma Research Center of Beijing, Beijing Chao-Yang Hospital, Capital Medical University , Beijing , China
| | - Yan-Chen Li
- a Department of Hematology , Myeloma Research Center of Beijing, Beijing Chao-Yang Hospital, Capital Medical University , Beijing , China
| | - Yun Leng
- a Department of Hematology , Myeloma Research Center of Beijing, Beijing Chao-Yang Hospital, Capital Medical University , Beijing , China
| | - Yu Tang
- b Department of Cardiology , Heart Failure Center, Capital Medical University, Beijing Chao-Yang Hospital , Beijing , China.,c Beijing Key Laboratory of Metabolic Disorders Related Cardiovascular Diseases , Beijing , China
| | - Lin Xu
- b Department of Cardiology , Heart Failure Center, Capital Medical University, Beijing Chao-Yang Hospital , Beijing , China.,c Beijing Key Laboratory of Metabolic Disorders Related Cardiovascular Diseases , Beijing , China
| | - Jia-Mei Liu
- b Department of Cardiology , Heart Failure Center, Capital Medical University, Beijing Chao-Yang Hospital , Beijing , China.,c Beijing Key Laboratory of Metabolic Disorders Related Cardiovascular Diseases , Beijing , China
| | - Hua Wang
- b Department of Cardiology , Heart Failure Center, Capital Medical University, Beijing Chao-Yang Hospital , Beijing , China.,c Beijing Key Laboratory of Metabolic Disorders Related Cardiovascular Diseases , Beijing , China
| | - Xin Wang
- b Department of Cardiology , Heart Failure Center, Capital Medical University, Beijing Chao-Yang Hospital , Beijing , China.,c Beijing Key Laboratory of Metabolic Disorders Related Cardiovascular Diseases , Beijing , China
| | - Juan Zhang
- b Department of Cardiology , Heart Failure Center, Capital Medical University, Beijing Chao-Yang Hospital , Beijing , China.,c Beijing Key Laboratory of Metabolic Disorders Related Cardiovascular Diseases , Beijing , China
| | - Wen-Shu Zhao
- b Department of Cardiology , Heart Failure Center, Capital Medical University, Beijing Chao-Yang Hospital , Beijing , China.,c Beijing Key Laboratory of Metabolic Disorders Related Cardiovascular Diseases , Beijing , China
| | - Wen-Ming Chen
- a Department of Hematology , Myeloma Research Center of Beijing, Beijing Chao-Yang Hospital, Capital Medical University , Beijing , China
| | - Lin Zhang
- b Department of Cardiology , Heart Failure Center, Capital Medical University, Beijing Chao-Yang Hospital , Beijing , China.,c Beijing Key Laboratory of Metabolic Disorders Related Cardiovascular Diseases , Beijing , China
| |
Collapse
|
|
4
|
Sun Z, Zheng F, Wu S, Liu Y, Guo H, Liu Y. Triplet versus doublet combination regimens for the treatment of relapsed or refractory multiple myeloma: A meta-analysis of phase III randomized controlled trials. Crit Rev Oncol Hematol 2017; 113:249-255. [PMID: 28427514 DOI: 10.1016/j.critrevonc.2017.03.018] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/09/2016] [Revised: 03/06/2017] [Accepted: 03/15/2017] [Indexed: 10/19/2022] Open
Abstract
During the past decades, several prospective trials had been conducted to assess the efficacy and toxicities of triplet versus doublet combination regimens for the treatment of relapsed or refractory multiple myeloma (RRMM), but the results were controversial. We thus performed a systematic literature search to identify relevant trials. Summary hazard ratios (HRs), relative risks (RRs), and 95% confidence intervals (95%CIs) were calculated. A total of 3197 RRMM patients were included for analysis. The pooled results demonstrated that triplet combination therapies significantly improve OS (HR 0.83, 95%CI: 0.71-0.94, p=0.004) and PFS (HR 0.68, 95%CI: 0.62-0.74, p<0.001). The pooled RRs of ORR, very good partial response (VGPR) and complete response (CR) with triplets vs. doublets were 1.19 (95%CI: 1.10-1.27), 1.44 (95%CI: 1.18-1.77), and 1.76 (95%CI: 1.04-2.97), respectively, indicating that the RRs of achieving deeper responses were higher with triplets, though the RRs of overall≥grade 3 adverse events (RR 1.11, p=0.001) and ≥grade 3 thrombocytopenia (RR 1.64, p=0.009) was higher with triplets. In conclusion, our meta-analysis demonstrated that triplet regimens result in improved OS, PFS, ORR, VGPR, and CR when compared to doublets, though the risk of grade 3 and 4 adverse events were higher with triplets.
Collapse
Affiliation(s)
- Zhiqiang Sun
- Department of Heamatology, Shenzhen Hospital of Southern Medical University, Shenzhen 518101, China.
| | - Fang Zheng
- Department of Heamatology, The Affiliated Baiyun Hospital of Guizhou Medical University, Guiyang 550014, China
| | - Suwan Wu
- Department of Clinical medicine, Southern Medical University, Guangzhou 5100100, China
| | - Yanjuan Liu
- Department of Clinical medicine Guizhou Medical University, Guiyang 550004, China
| | - Hehe Guo
- Department of Clinical medicine Guizhou Medical University, Guiyang 550004, China
| | - Yichen Liu
- Department of Clinical medicine Guizhou Medical University, Guiyang 550004, China
| |
Collapse
|
|
5
|
Abstract
Multiple myeloma (MM) is the second most common hematological malignancy and is characterized by the aberrant proliferation of terminally differentiated plasma B cells with impairment in apoptosis capacity. Particularly, osteolytic bone diseases and renal failure resulting from hyperparaproteinemia and hypercalcemia have been the major serious sequelae that are inextricably linked with MM tumor progression. Despite the introduction of new treatment regimens, problematic neuropathy, thrombocytopenia, drug resistance and high MM relapse rates continue to plague the current therapies. New chemical agents are in development on the basis of understanding several signaling pathways and molecular mechanisms like tumor necrosis factor-α, proteasome, PI3K and MARKs. This review focuses on the most recent patents and clinical trials in the development of new medicine for the treatment of multiple myeloma. Furthermore, the important signaling pathways involved in the proliferation, survival and apoptosis of myeloma cells will be discussed.
Collapse
|
|
6
|
Jacobs C, Graham ID, Makarski J, Chassé M, Fergusson D, Hutton B, Clemons M. Clinical practice guidelines and consensus statements in oncology--an assessment of their methodological quality. PLoS One 2014; 9:e110469. [PMID: 25329669 PMCID: PMC4201546 DOI: 10.1371/journal.pone.0110469] [Citation(s) in RCA: 28] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/20/2014] [Accepted: 09/22/2014] [Indexed: 01/20/2023] Open
Abstract
BACKGROUND Consensus statements and clinical practice guidelines are widely available for enhancing the care of cancer patients. Despite subtle differences in their definition and purpose, these terms are often used interchangeably. We systematically assessed the methodological quality of consensus statements and clinical practice guidelines published in three commonly read, geographically diverse, cancer-specific journals. Methods Consensus statements and clinical practice guidelines published between January 2005 and September 2013 in Current Oncology, European Journal of Cancer and Journal of Clinical Oncology were evaluated. Each publication was assessed using the Appraisal of Guidelines for Research and Evaluation II (AGREE II) rigour of development and editorial independence domains. For assessment of transparency of document development, 7 additional items were taken from the Institute of Medicine's standards for practice guidelines and the Journal of Clinical Oncology guidelines for authors of guidance documents. METHODS Consensus statements and clinical practice guidelines published between January 2005 and September 2013 in Current Oncology, European Journal of Cancer and Journal of Clinical Oncology were evaluated. Each publication was assessed using the Appraisal of Guidelines for Research and Evaluation II (AGREE II) rigour of development and editorial independence domains. For assessment of transparency of document development, 7 additional items were taken from the Institute of Medicine's standards for practice guidelines and the Journal of Clinical Oncology guidelines for authors of guidance documents. FINDINGS Thirty-four consensus statements and 67 clinical practice guidelines were evaluated. The rigour of development score for consensus statements over the three journals was 32% lower than that of clinical practice guidelines. The editorial independence score was 15% lower for consensus statements than clinical practice guidelines. One journal scored consistently lower than the others over both domains. No journals adhered to all the items related to the transparency of document development. One journal's consensus statements endorsed a product made by the sponsoring pharmaceutical company in 64% of cases. CONCLUSION Guidance documents are an essential part of oncology care and should be subjected to a rigorous and validated development process. Consensus statements had lower methodological quality than clinical practice guidelines using AGREE II. At a minimum, journals should ensure that that all consensus statements and clinical practice guidelines adhere to AGREE II criteria. Journals should consider explicitly requiring guidelines to declare pharmaceutical company sponsorship and to identify the sponsor's product to enhance transparency.
Collapse
Affiliation(s)
- Carmel Jacobs
- Division of Medical Oncology, The Ottawa Hospital Cancer Centre and Department of Medicine, University of Ottawa, Ottawa, Ontario, Canada
| | - Ian D. Graham
- Department of Epidemiology and Community Medicine, University of Ottawa, Ottawa, Ontario, Canada
- Ottawa Hospital Research Institute and University of Ottawa, Department of Medicine, Ottawa, Ontario, Canada
| | | | - Michaël Chassé
- Department of Epidemiology and Community Medicine, University of Ottawa, Ottawa, Ontario, Canada
| | - Dean Fergusson
- Department of Epidemiology and Community Medicine, University of Ottawa, Ottawa, Ontario, Canada
- Ottawa Hospital Research Institute and University of Ottawa, Department of Medicine, Ottawa, Ontario, Canada
| | - Brian Hutton
- Department of Epidemiology and Community Medicine, University of Ottawa, Ottawa, Ontario, Canada
| | - Mark Clemons
- Division of Medical Oncology, The Ottawa Hospital Cancer Centre and Department of Medicine, University of Ottawa, Ottawa, Ontario, Canada
- Ottawa Hospital Research Institute and University of Ottawa, Department of Medicine, Ottawa, Ontario, Canada
| |
Collapse
|
|
7
|
Kouroukis C, Baldassarre F, Haynes A, Imrie K, Reece D, Cheung M. Bortezomib in Multiple Myeloma: A Practice Guideline. Clin Oncol (R Coll Radiol) 2014; 26:110-9. [DOI: 10.1016/j.clon.2013.11.022] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/12/2013] [Revised: 10/07/2013] [Accepted: 10/21/2013] [Indexed: 11/25/2022]
|